The therapeutic monitoring of antimicrobial agents

British Journal of Clinical Pharmacology

Volumn 52, Issue SUPPL. 1, 2001, Pages 35-43

  Begg, Evan J ^a,b   Barclay, Murray L ^a   Kirkpatrick, Carl M J ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antimicrobial agents; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; FLUCYTOSINE; GENTAMICIN; ITRACONAZOLE; NETILMICIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG PROTEIN BINDING; HUMAN; INFECTION; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; TIME;

EID: 0034844915     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.00377.x     Document Type: Article

References (77)

1. Aminoglycosides - 50 years on
2. Design and optimisation of dosage regimens
3. Rapid individualization of gentamicin dosage regimens in 66 burn patients
4. Wide variation in single daily dose aminoglycoside pharmacokinetics in patients with burn injuries
5. Aminoglycoside toxicity and relation to dose regimen
6. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis
7. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia
8. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia
9. Once versus thrice daily gentamicin in patients with serious infections
10. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides
11. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: Comparative trial with netilmicin plus cefriaxone
12. A suggested approach to once-daily aminoglycoside dosing
13. Use of aminoglycosides in elderly patients-pharmacokinetic and clinical considerations
14. Kinetic model for gentamicin dosing with the use of individual patient parameters
15. Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations
16. A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients
17. A Bayesian feedback method of aminoglycoside dosing
18. Serum aminoglycoside concentrations: The case for routine monitoring
19. Experience with a once-daily aminoglycoside program administered to 2184 adult patients
20. Ototoxicity induced by once-daily gentamicin
21. Validation of the Hartford nomogram in trauma surgery patients
22. Comparison of two Bayesian approaches to dose-individualisation for once daily dosing regimens
23. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients
24. Handbook on injectable drugs, sixth edition
25. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis
26. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization
27. Impact of goal-orientated and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis
28. Once-daily aminoglycoside dosing: Impact on requests and costs of therapeutic drug monitoring
29. Experience with once daily dosing of gentamicin: Considerations regarding dosing and monitoring
30. Routine monitoring of gentamicin serum concentrations in pediatric patients with normal renal function is unnecessary
31. Routine monitoring of serum vancomycin concentrations: Waiting for proof of its value
32. Vancomycin therapeutic drug monitoring: Is it necessary?
33. Why monitor peak vancomycin concentrations?
34. Vancomycin toxicity. What is the evidence for dose dependency?
35. How vancomycin is used in clinical practice - A survey
36. Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides
37. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures
38. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis
39. Nephrotoxicity of vancomycin, alone and with an aminoglycoside
40. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy
41. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin
42. Vancomycin-induced histamine release and 'red man syndrome': Comparison of 1 and 2 hour infusions
43. A simplified dosing method for initiating vancomycin therapy
44. Pharmacokinetics of vancomycin in patients with various degrees of renal function
45. Pharmacokinetics of vancomycin
46. Therapeutic drug monitoring of vancomycin in a morbidly obese patient
47. Errors in assuming a one-compartment model for vancomycin
48. Evaluation of a Bayesian method for predicting vancomycin dosing
49. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens
50. Individualizing vancomycin dosage regimens: One- versus two compartment Bayesian models
51. Vancomycin monitoring: One or two serum levels?
52. Measurement of vancomycin in renally impaired
53. The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline
54. Overestimation of vancomycin concentrations utilising fluorescence polarising immunoassay in patients on peritoneal dialysis
55. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease
56. Impact of vancomycin therapeutic drug monitoring on patient care
57. Evaluation of a method for individualising vancomycin therapy: Experience in 205 patients
58. Outcome assessment of minimizing vancomycin and dosing adjustments
59. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy
60. The comparative efficacy and safety of teicoplanin and vancomycin
61. Fluorescence polarization immunoassay: Does it always represent a reliable method to monitor treatment with teicoplanin? Comparison with data obtained by high-performance liquid chromatography
62. Therapeutic monitoring of antimicrobials
63. Pharmacokinetics of a single dose of teicoplanin in burn patients
64. Comparison of a vancomycin and teicoplanin-induced histamine release and 'red man syndrome'
65. Therapeutic drug monitoring of systemic antifungal therapy
66. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
67. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutical applications
68. Bone marrow toxicity associated with 5 fluorocytosine therapy
69. Flucytosine: Correlation between toxicity and pharmacokinetic parameters
70. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
71. Flucytosine - What is its future?
72. Interaction of azoles with rifampin, phenytoin and carbamazepine: In vitro and clinical observations
73. Optimisation of intraconazole therapy using target drug concentrations
74. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogenic bone marrow transplant recipients
75. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: Preliminary results of two randomised studies
76. The in vitro antifungal spectrum of itraconazole
77. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography